PAIOF (Paion AG) YoY EBITDA Growth: -159.46% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PAIOF Paion AG PAIOF
10 GF Score
Price $0.07
View Full Analysis

What is Paion AG YoY EBITDA Growth?

Paion AG PAIOF 10 YoY EBITDA Growth is -159.46% as of Jun. 2023. GuruFocus rates PAIOF with a GF Score™ of 10/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Paion AG's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was -159.46%.

Paion AG's EBITDA per Share for the six months ended in Jun. 2023 was $-1.06.

Paion AG YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Paion AG's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion AG YoY EBITDA Growth Chart

Paion AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.21 31.01 123.09 -951.69 121.11

Paion AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.86 -213.78 229.70 34.04 -159.46
PAIOF
10GF Score
Paion AG PAIOF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paion AG YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Paion AG's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(0.64--3.032)/ | -3.032 |
=121.11 %

Paion AG's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (Q: Jun. 2023 )
=(EBITDA per Share (Q: Jun. 2023 )-EBITDA per Share (Q: Jun. 2022 )) / | EBITDA per Share (Q: Jun. 2022 )) |
=(-1.062-1.786)/ | 1.786 |
=-159.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -159.46% mean?
Paion AG (PAIOF) has a YoY EBITDA Growth of -159.46% as of Jun. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Paion AG and its competitors.
Is Paion AG's YoY EBITDA Growth too high?
Paion AG's current YoY EBITDA Growth is -159.46%. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's YoY EBITDA Growth compare to ZTS and NBIX?
Paion AG's YoY EBITDA Growth of -159.46% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Paion AG and its competitors. Paion AG's current YoY EBITDA Growth is -159.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current YoY EBITDA Growth of -159.46%. The current YoY EBITDA Growth is -159.46%. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Paion AG (PAIOF), the current YoY EBITDA Growth is -159.46% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paion AG Business Description

Address Heussstrasse 25, Aachen, DEU, 52078
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score

Get the complete analysis for PAIOF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price